Phaseline

Companies › CUTISS

CUTISS: clinical trials, targets and expected readouts

1 active drug program in 2 registered trials: 1 Phase 3, 1 Phase 2; Other; next expected readout Jun 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
EHSG-KF (denovoSkin)
Autologous dermo-epidermal skin substitute
–Phase 3BurnsJun 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06745557EHSG-KF (denovoSkin)Phase 3BurnsOtherJun 2027
NCT03229564EHSG-KF (denovoSkin)Phase 2BurnsOtherJun 2028

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Gameto Merz Aesthetics DBV Technologies Merz North America CellTherX

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.